<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);
    }
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 7.3 - COPD | MD3 SCP Cases</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 7.3 - COPD | MD3 SCP Cases">
  <meta name="description" content="Chronic obstructive pulmonary disease case study for medical students.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://md3-scp.netlify.app/cases/case7_3.html">
  <meta property="og:title" content="Case 7.3 - COPD">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="Chronic obstructive pulmonary disease case study for medical students.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">

  <!-- Twitter -->
  <meta property="twitter:card" content="summary">
  <meta property="twitter:title" content="Case 7.3 - COPD">
  <meta property="twitter:description" content="Chronic obstructive pulmonary disease case study for medical students.">
  <meta property="twitter:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">

  <link rel="stylesheet" href="../../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 7.3 – COPD</h1>
    <p class="meta"><strong>Category:</strong> Respiratory System | <strong>Discipline:</strong> Medicine | <strong>Setting:</strong> General Practice</p>

    <h2>Case</h2>
    <p>Min Lai, aged 48 years presents with a chronic persistent cough. She complains of breathlessness and of morning production of sputum. On further questioning she scores a 3 on the modified MRC dyspnoea scale.</p>

    <h2>Questions</h2>

    <div class="question">
      <strong>1. What is Chronic Obstructive Pulmonary Disease (COPD)?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterised by persistent respiratory symptoms and airflow limitation.</p>

        <p><strong>Key Features:</strong></p>
        <ul>
          <li>The airflow limitation is due to airway and/or alveolar abnormalities</li>
          <li>Usually caused by significant exposure to noxious particles or gases</li>
          <li>The most common respiratory symptoms include dyspnoea, cough and/or sputum production</li>
          <li>These symptoms may be under-reported by patients</li>
        </ul>

        <p><strong>Pathophysiology:</strong></p>
        <ul>
          <li>COPD encompasses two main conditions:
            <ul>
              <li><strong>Chronic Bronchitis:</strong> Clinically defined as chronic productive cough for 3 months in each of 2 successive years (when other causes of chronic cough have been excluded)</li>
              <li><strong>Emphysema:</strong> Pathologically defined as permanent destructive enlargement of the air spaces distal to the terminal bronchioles</li>
            </ul>
          </li>
          <li>Most patients have features of both conditions</li>
          <li>Characterised by chronic inflammation throughout the airways, parenchyma, and pulmonary vasculature</li>
        </ul>

        <p><strong>Risk Factors:</strong></p>
        <ul>
          <li><strong>Cigarette smoking:</strong> The most important risk factor (accounts for 80-90% of COPD)</li>
          <li><strong>Occupational exposures:</strong> Dust, chemicals, and fumes</li>
          <li><strong>Indoor air pollution:</strong> Biomass fuel used for cooking and heating in poorly ventilated dwellings</li>
          <li><strong>Outdoor air pollution:</strong> Though less important than smoking</li>
          <li><strong>Genetic factors:</strong> Alpha-1 antitrypsin deficiency (rare)</li>
          <li><strong>Age:</strong> Usually develops in middle age</li>
          <li><strong>Childhood factors:</strong> Low birth weight, respiratory infections</li>
        </ul>

        <p><strong>Natural History:</strong></p>
        <ul>
          <li>Progressive disease that worsens over time</li>
          <li>Rate of decline accelerated by continued smoking</li>
          <li>Punctuated by exacerbations</li>
          <li>Associated with significant comorbidity</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>2. Explain the modified MRC dyspnoea scale.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>The modified Medical Research Council (mMRC) dyspnoea scale is a simple and validated tool used to assess the degree of breathlessness related to activities.</p>

        <p><strong>Modified MRC Dyspnoea Scale:</strong></p>
        <ul>
          <li><strong>Grade 0:</strong> I only get breathless with strenuous exercise</li>
          <li><strong>Grade 1:</strong> I get short of breath when hurrying on level ground or walking up a slight hill</li>
          <li><strong>Grade 2:</strong> On level ground, I walk slower than people of the same age because of breathlessness, or I have to stop for breath when walking at my own pace</li>
          <li><strong>Grade 3:</strong> I stop for breath after walking about 100 metres or after a few minutes on level ground</li>
          <li><strong>Grade 4:</strong> I am too breathless to leave the house or I am breathless when dressing</li>
        </ul>

        <p><strong>Clinical Utility:</strong></p>
        <ul>
          <li>Simple and quick to administer</li>
          <li>Correlates well with other measures of health status</li>
          <li>Predicts mortality in COPD</li>
          <li>Used in conjunction with spirometry and exacerbation history to guide treatment</li>
          <li>Grades 0-1 usually indicate mild symptoms</li>
          <li>Grades 2-4 indicate more significant symptoms requiring more intensive treatment</li>
        </ul>

        <p><strong>In This Case:</strong></p>
        <p>Min Lai scores a 3 on the mMRC scale, meaning she stops for breath after walking about 100 metres or after a few minutes on level ground. This indicates significant breathlessness affecting her daily activities and suggests moderate to severe COPD.</p>
      </div>
    </div>

    <div class="question">
      <strong>3. What further history and examination would you undertake?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Further History:</strong></p>

        <p><strong>Respiratory History:</strong></p>
        <ul>
          <li><strong>Smoking history:</strong> Quantify in pack-years (packs per day × years smoked)</li>
          <li><strong>Cough:</strong> Duration, frequency, character, productive vs dry</li>
          <li><strong>Sputum:</strong> Volume, colour, consistency, haemoptysis</li>
          <li><strong>Breathlessness:</strong> Onset, progression, precipitating factors, exercise tolerance</li>
          <li><strong>Wheeze:</strong> Frequency, triggers</li>
          <li><strong>Chest tightness</strong></li>
          <li><strong>Exacerbations:</strong> Frequency, severity, hospitalisations, need for ventilation</li>
          <li><strong>Diurnal variation:</strong> Symptoms worse at particular times of day</li>
        </ul>

        <p><strong>Occupational and Environmental History:</strong></p>
        <ul>
          <li>Occupational exposures to dust, fumes, chemicals</li>
          <li>Exposure to biomass fuels</li>
          <li>Passive smoking exposure</li>
        </ul>

        <p><strong>Past Medical History:</strong></p>
        <ul>
          <li>Childhood respiratory problems, asthma</li>
          <li>Previous tuberculosis or other lung disease</li>
          <li>Cardiovascular disease</li>
          <li>Osteoporosis</li>
          <li>Depression and anxiety</li>
        </ul>

        <p><strong>Family History:</strong></p>
        <ul>
          <li>COPD in family members</li>
          <li>Alpha-1 antitrypsin deficiency</li>
          <li>Other respiratory diseases</li>
        </ul>

        <p><strong>Impact on Daily Life:</strong></p>
        <ul>
          <li>Ability to perform activities of daily living</li>
          <li>Sleep disturbance</li>
          <li>Impact on work</li>
          <li>Psychological impact (anxiety, depression)</li>
          <li>Social isolation</li>
        </ul>

        <p><strong>Physical Examination:</strong></p>

        <p><strong>General Inspection:</strong></p>
        <ul>
          <li>Respiratory distress, use of accessory muscles</li>
          <li>Pursed-lip breathing</li>
          <li>Barrel-shaped chest (hyperinflation)</li>
          <li>Cachexia (advanced disease)</li>
          <li>Peripheral oedema (cor pulmonale)</li>
          <li>Cyanosis</li>
          <li>Nicotine staining of fingers</li>
        </ul>

        <p><strong>Respiratory Examination:</strong></p>
        <ul>
          <li><strong>Inspection:</strong> Increased AP diameter, reduced chest expansion</li>
          <li><strong>Palpation:</strong> Reduced chest expansion, decreased tactile fremitus</li>
          <li><strong>Percussion:</strong> Hyperresonance (emphysema)</li>
          <li><strong>Auscultation:</strong>
            <ul>
              <li>Decreased breath sounds</li>
              <li>Prolonged expiratory phase</li>
              <li>Wheeze (particularly on expiration or forced expiration)</li>
              <li>Coarse crackles (if bronchitis predominant)</li>
            </ul>
          </li>
        </ul>

        <p><strong>Cardiovascular Examination:</strong></p>
        <ul>
          <li>Signs of cor pulmonale: elevated JVP, right ventricular heave, loud P2, tricuspid regurgitation</li>
          <li>Peripheral oedema</li>
        </ul>

        <p><strong>Other:</strong></p>
        <ul>
          <li>BMI (cachexia or obesity)</li>
          <li>Oxygen saturation</li>
          <li>Blood pressure, heart rate, respiratory rate</li>
        </ul>

        <p><em>Note: In early COPD, physical examination may be normal. Examination findings become more apparent as disease progresses.</em></p>
      </div>
    </div>

    <div class="question">
      <strong>4. What investigations are ordered to assess COPD?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Essential Investigations:</strong></p>

        <p><strong>1. Spirometry (Mandatory for Diagnosis):</strong></p>
        <ul>
          <li>Confirms the presence of airflow limitation</li>
          <li><strong>Diagnostic criteria:</strong> Post-bronchodilator FEV₁/FVC < 0.70 confirms persistent airflow limitation</li>
          <li><strong>Severity assessment:</strong> Based on FEV₁ % predicted:
            <ul>
              <li>GOLD 1 (Mild): FEV₁ ≥ 80% predicted</li>
              <li>GOLD 2 (Moderate): 50% ≤ FEV₁ < 80% predicted</li>
              <li>GOLD 3 (Severe): 30% ≤ FEV₁ < 50% predicted</li>
              <li>GOLD 4 (Very Severe): FEV₁ < 30% predicted</li>
            </ul>
          </li>
          <li>Should be performed when patient is clinically stable</li>
          <li>Unlike asthma, shows limited reversibility to bronchodilators</li>
        </ul>

        <p><strong>2. Chest X-ray:</strong></p>
        <ul>
          <li>Usually normal in mild to moderate COPD</li>
          <li>May show hyperinflation (flattened hemidiaphragms, increased retrosternal space)</li>
          <li>Bullae (large air spaces)</li>
          <li>Attenuated peripheral vascular markings</li>
          <li>Useful to exclude alternative diagnoses (lung cancer, tuberculosis, pulmonary fibrosis)</li>
          <li>May show complications (pneumothorax, pneumonia)</li>
        </ul>

        <p><strong>3. Pulse Oximetry:</strong></p>
        <ul>
          <li>Assess oxygenation</li>
          <li>If SpO₂ < 92%, perform arterial blood gas</li>
        </ul>

        <p><strong>Additional Investigations (Selected Cases):</strong></p>

        <p><strong>4. Arterial Blood Gas:</strong></p>
        <ul>
          <li>Indicated if: FEV₁ < 50% predicted, SpO₂ < 92%, signs of respiratory failure or cor pulmonale</li>
          <li>Assesses hypoxemia and hypercapnia</li>
          <li>Guides need for long-term oxygen therapy</li>
        </ul>

        <p><strong>5. Full Blood Count:</strong></p>
        <ul>
          <li>Exclude anaemia (worsens breathlessness)</li>
          <li>Polycythaemia (chronic hypoxia)</li>
          <li>Raised eosinophils may indicate asthma-COPD overlap or predict response to ICS</li>
        </ul>

        <p><strong>6. Alpha-1 Antitrypsin Level:</strong></p>
        <ul>
          <li>If COPD develops at young age (< 45 years)</li>
          <li>Minimal smoking history</li>
          <li>Family history of early-onset COPD or liver disease</li>
          <li>Lower lobe predominant emphysema</li>
        </ul>

        <p><strong>7. CT Chest (High Resolution):</strong></p>
        <ul>
          <li>Not routinely required for diagnosis</li>
          <li>Useful if considering surgical interventions (bullectomy, lung volume reduction surgery)</li>
          <li>Suspected bronchiectasis or interstitial lung disease</li>
          <li>Investigation of haemoptysis or weight loss (exclude malignancy)</li>
          <li>Can quantify emphysema distribution and severity</li>
        </ul>

        <p><strong>8. Sputum Culture:</strong></p>
        <ul>
          <li>During acute exacerbations</li>
          <li>If recurrent infections</li>
          <li>Exclude tuberculosis in high-risk patients</li>
        </ul>

        <p><strong>9. ECG and Echocardiography:</strong></p>
        <ul>
          <li>If suspected cor pulmonale or coexistent heart disease</li>
          <li>ECG may show: right axis deviation, right ventricular hypertrophy, P pulmonale, right bundle branch block</li>
          <li>Echo assesses right ventricular function and pulmonary hypertension</li>
        </ul>

        <p><strong>10. Exercise Tests:</strong></p>
        <ul>
          <li>6-minute walk test: Simple assessment of functional capacity</li>
          <li>Cardiopulmonary exercise testing: Detailed assessment in selected patients</li>
          <li>Useful for assessing disability, prognosis, and response to interventions</li>
        </ul>

        <p><strong>Assessment of Symptom Burden:</strong></p>
        <ul>
          <li>CAT (COPD Assessment Test): Validated questionnaire to quantify impact of COPD</li>
          <li>mMRC dyspnoea scale</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>5. Summarise the pathophysiology of COPD.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>The pathophysiology of COPD involves chronic inflammation, structural changes, and progressive airflow limitation.</p>

        <p><strong>1. Chronic Inflammation:</strong></p>
        <ul>
          <li><strong>Trigger:</strong> Inhalation of noxious particles and gases (primarily cigarette smoke)</li>
          <li><strong>Inflammatory response:</strong>
            <ul>
              <li>Abnormal inflammatory response in genetically susceptible individuals</li>
              <li>Involves neutrophils, macrophages, and CD8+ T lymphocytes</li>
              <li>Release of inflammatory mediators (cytokines, chemokines)</li>
              <li>Protease-antiprotease imbalance</li>
              <li>Oxidative stress</li>
            </ul>
          </li>
          <li>Inflammation affects the entire respiratory system: airways, parenchyma, and pulmonary vasculature</li>
          <li>Inflammation persists even after smoking cessation</li>
        </ul>

        <p><strong>2. Airway Changes (Chronic Bronchitis Component):</strong></p>
        <ul>
          <li><strong>Large airways (central airways):</strong>
            <ul>
              <li>Mucous gland hyperplasia and goblet cell metaplasia</li>
              <li>Increased mucus production</li>
              <li>Ciliary dysfunction</li>
              <li>Chronic productive cough</li>
            </ul>
          </li>
          <li><strong>Small airways (< 2mm diameter):</strong>
            <ul>
              <li>Primary site of airflow obstruction</li>
              <li>Airway wall thickening due to inflammation and fibrosis</li>
              <li>Smooth muscle hypertrophy</li>
              <li>Mucus plugging</li>
              <li>Loss of alveolar attachments (reduced elastic recoil)</li>
              <li>Progressive narrowing and obliteration</li>
            </ul>
          </li>
        </ul>

        <p><strong>3. Parenchymal Changes (Emphysema Component):</strong></p>
        <ul>
          <li><strong>Alveolar destruction:</strong>
            <ul>
              <li>Permanent enlargement of airspaces distal to terminal bronchioles</li>
              <li>Destruction of alveolar walls without obvious fibrosis</li>
              <li>Loss of elastic recoil</li>
            </ul>
          </li>
          <li><strong>Types of emphysema:</strong>
            <ul>
              <li><strong>Centrilobular:</strong> Affects respiratory bronchioles, upper lobes, smoking-related</li>
              <li><strong>Panlobular:</strong> Affects entire acinus, lower lobes, alpha-1 antitrypsin deficiency</li>
              <li><strong>Paraseptal:</strong> Distal acinus, subpleural, associated with spontaneous pneumothorax</li>
            </ul>
          </li>
          <li><strong>Mechanisms:</strong>
            <ul>
              <li>Protease-antiprotease imbalance (excess proteases destroy elastin)</li>
              <li>Apoptosis of alveolar cells</li>
              <li>Loss of capillary bed</li>
            </ul>
          </li>
        </ul>

        <p><strong>4. Vascular Changes:</strong></p>
        <ul>
          <li>Thickening of vessel walls (intimal hyperplasia, smooth muscle hypertrophy)</li>
          <li>Loss of capillaries in alveolar walls</li>
          <li>Endothelial dysfunction</li>
          <li>Results in pulmonary hypertension in advanced disease</li>
        </ul>

        <p><strong>5. Consequences of Pathological Changes:</strong></p>
        <ul>
          <li><strong>Airflow limitation:</strong>
            <ul>
              <li>Small airway narrowing and obliteration (major component)</li>
              <li>Loss of elastic recoil (emphysema)</li>
              <li>Increased airway resistance</li>
              <li>Predominantly affects expiration</li>
            </ul>
          </li>
          <li><strong>Gas trapping and hyperinflation:</strong>
            <ul>
              <li>Incomplete expiration</li>
              <li>Dynamic hyperinflation (worsens during exercise)</li>
              <li>Increased work of breathing</li>
              <li>Flattened diaphragm with reduced mechanical efficiency</li>
            </ul>
          </li>
          <li><strong>Gas exchange abnormalities:</strong>
            <ul>
              <li>Ventilation-perfusion (V/Q) mismatch</li>
              <li>Hypoxemia</li>
              <li>Hypercapnia (in advanced disease)</li>
            </ul>
          </li>
          <li><strong>Mucus hypersecretion:</strong>
            <ul>
              <li>Chronic productive cough</li>
              <li>Predisposition to infection</li>
            </ul>
          </li>
          <li><strong>Pulmonary hypertension and cor pulmonale:</strong>
            <ul>
              <li>Vascular changes</li>
              <li>Hypoxic vasoconstriction</li>
              <li>Loss of capillary bed</li>
              <li>Right ventricular dysfunction</li>
            </ul>
          </li>
        </ul>

        <p><strong>6. Systemic Effects:</strong></p>
        <ul>
          <li>Weight loss and cachexia</li>
          <li>Skeletal muscle dysfunction</li>
          <li>Osteoporosis</li>
          <li>Cardiovascular disease</li>
          <li>Depression and anxiety</li>
          <li>Increased risk of lung cancer</li>
        </ul>

        <p><em>The pathological changes in COPD are largely irreversible, but progression can be slowed (particularly by smoking cessation) and symptoms can be managed with appropriate therapy.</em></p>
      </div>
    </div>

    <div class="question">
      <strong>6. Summarise the management of chronic stable COPD.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p>Management of stable COPD aims to reduce symptoms, decrease frequency and severity of exacerbations, and improve exercise tolerance and health status.</p>

        <p><strong>1. Non-Pharmacological Management:</strong></p>

        <p><strong>Smoking Cessation:</strong></p>
        <ul>
          <li>THE MOST IMPORTANT INTERVENTION</li>
          <li>Only intervention proven to slow decline in lung function</li>
          <li>Offer support, counselling, and pharmacotherapy (nicotine replacement, varenicline, bupropion)</li>
          <li>Should be addressed at every clinical encounter</li>
        </ul>

        <p><strong>Pulmonary Rehabilitation:</strong></p>
        <ul>
          <li>Comprehensive program including exercise training, education, and behavioural change</li>
          <li>Improves dyspnoea, exercise capacity, and quality of life</li>
          <li>Reduces hospitalizations</li>
          <li>Indicated for patients with mMRC ≥ 1 or symptomatic patients</li>
        </ul>

        <p><strong>Vaccinations:</strong></p>
        <ul>
          <li><strong>Influenza vaccine:</strong> Annually</li>
          <li><strong>Pneumococcal vaccine:</strong> Once, with revaccination after 5 years in high-risk patients</li>
          <li><strong>COVID-19 vaccine:</strong> As per current guidelines</li>
        </ul>

        <p><strong>Nutrition:</strong></p>
        <ul>
          <li>Nutritional support for patients who are underweight</li>
          <li>Weight reduction for obese patients</li>
        </ul>

        <p><strong>2. Pharmacological Management (Stepwise Approach):</strong></p>

        <p><strong>Initial Treatment (All Patients):</strong></p>
        <ul>
          <li><strong>Short-acting bronchodilators (as needed):</strong>
            <ul>
              <li>Short-acting β2-agonist (SABA): Salbutamol</li>
              <li>Short-acting muscarinic antagonist (SAMA): Ipratropium</li>
              <li>Use as needed for symptom relief</li>
            </ul>
          </li>
        </ul>

        <p><strong>Further Treatment Based on GOLD Classification:</strong></p>
        <p>Treatment escalation depends on symptom burden (mMRC or CAT score) and exacerbation history.</p>

        <p><strong>Group B (More Symptoms, Few Exacerbations):</strong></p>
        <ul>
          <li><strong>Long-acting bronchodilator monotherapy:</strong>
            <ul>
              <li>LABA (e.g., salmeterol, formoterol) OR</li>
              <li>LAMA (e.g., tiotropium, glycopyrronium)</li>
            </ul>
          </li>
          <li>LAMA may be preferred as first choice</li>
        </ul>

        <p><strong>If inadequate control:</strong></p>
        <ul>
          <li><strong>Dual long-acting bronchodilator therapy (LABA + LAMA)</strong></li>
          <li>More effective than monotherapy for symptoms and lung function</li>
          <li>Examples: Umeclidinium/vilanterol, tiotropium/olodaterol</li>
        </ul>

        <p><strong>Group E (Frequent Exacerbations):</strong></p>
        <ul>
          <li><strong>LAMA monotherapy</strong> (preferred initial treatment)</li>
          <li>More effective than LABA at preventing exacerbations</li>
        </ul>

        <p><strong>If further exacerbations:</strong></p>
        <ul>
          <li><strong>LABA + LAMA</strong></li>
        </ul>

        <p><strong>If still having exacerbations on LABA + LAMA:</strong></p>
        <ul>
          <li><strong>Consider blood eosinophil count:</strong>
            <ul>
              <li><strong>Eosinophils ≥ 300 cells/μL:</strong> Add ICS (triple therapy: LABA + LAMA + ICS)</li>
              <li><strong>Eosinophils < 300 cells/μL:</strong> Continue LABA + LAMA, consider alternative approaches</li>
            </ul>
          </li>
          <li>Triple therapy examples: Fluticasone furoate/umeclidinium/vilanterol</li>
        </ul>

        <p><strong>Additional Therapies:</strong></p>
        <ul>
          <li><strong>Chronic oral corticosteroids:</strong> NOT recommended due to significant side effects</li>
          <li><strong>Oral theophylline:</strong> May be considered if inadequate response to other bronchodilators; narrow therapeutic window</li>
          <li><strong>Oral phosphodiesterase-4 inhibitor (roflumilast):</strong> In severe COPD with chronic bronchitis and frequent exacerbations despite triple therapy</li>
          <li><strong>Mucolytics:</strong> Limited evidence; may reduce exacerbations in selected patients not on ICS</li>
          <li><strong>Prophylactic antibiotics (azithromycin):</strong> May reduce exacerbations in selected patients with frequent exacerbations</li>
        </ul>

        <p><strong>3. Oxygen Therapy:</strong></p>
        <ul>
          <li><strong>Long-term oxygen therapy (LTOT):</strong>
            <ul>
              <li>Indicated if: PaO₂ ≤ 7.3 kPa (55 mmHg) OR PaO₂ 7.3-8.0 kPa (55-60 mmHg) with evidence of cor pulmonale or polycythaemia</li>
              <li>Must be used for ≥ 15 hours per day to improve survival</li>
              <li>Assess when patient is stable (at least 4 weeks after exacerbation)</li>
              <li>Repeat assessment after 3 months</li>
            </ul>
          </li>
          <li><strong>Ambulatory oxygen:</strong> For patients who desaturate on exercise</li>
        </ul>

        <p><strong>4. Surgical and Interventional Approaches:</strong></p>
        <ul>
          <li><strong>Lung volume reduction surgery:</strong> Selected patients with upper lobe predominant emphysema</li>
          <li><strong>Bullectomy:</strong> If large bulla compressing surrounding lung</li>
          <li><strong>Lung transplantation:</strong> Highly selected patients with very severe COPD</li>
          <li><strong>Endobronchial valves:</strong> In selected patients with severe emphysema</li>
        </ul>

        <p><strong>5. Management of Comorbidities:</strong></p>
        <ul>
          <li>Cardiovascular disease</li>
          <li>Osteoporosis</li>
          <li>Depression and anxiety</li>
          <li>Gastroesophageal reflux</li>
          <li>Lung cancer screening in high-risk patients</li>
        </ul>

        <p><strong>6. Monitoring and Follow-up:</strong></p>
        <ul>
          <li>Regular review of symptoms, exacerbation frequency</li>
          <li>Spirometry annually or when clinically indicated</li>
          <li>Assess inhaler technique at every visit</li>
          <li>Reinforce smoking cessation</li>
          <li>Address patient concerns and optimize self-management</li>
        </ul>
      </div>
    </div>
  </div>

<!-- JavaScript -->  <script src="../../js/firebase-config.js"></script>
  <script src="../../js/dark-mode.js"></script>
  <script src="../../js/auth.js"></script>
  <script src="../../js/user-analytics.js"></script>
  <script src="../../js/analytics-integration.js"></script>
  <script src="../../js/completion-tracker.js"></script>
  <script src="../../js/flag-tracker.js"></script>
  <script src="../../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        
    }
      
    }
    
    }
// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      
    }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      
    }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          
    }
        }, 100);
      
    }
    });
    
    }
  </script>

</body>
</html>
